Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Oyster Point Pharma Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners and 3 distinct art units. NEAGU, IRINA is the busiest examiner, with 1 pending action assigned. The data shows that for the 3 pending office actions, there is no overlap in examiners or art units.
This distribution across 3 distinct examiners and 3 distinct art units implies that each patent application is being treated as an independent technical matter. Practitioners should note that the 3 pending office actions will likely follow different timelines and receive different types of rejections based on the 3 distinct art units involved. NEAGU, IRINA is one of three individuals currently shaping the company's pharmaceutical portfolio. The lack of concentration suggests that the company's current biotechnology efforts are technically diverse enough to trigger reviews from three separate specialized groups. Each of the 3 pending office actions requires a unique strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.8% | +57.2% |
| ISMAIL, REHANA | 1 | 75.5% | +35.7% |
| VIVLEMORE, TRACY ANN | 1 | 72.9% | +6.6% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559512 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18437748 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | ISMAIL, REHANA | 70d |
| 18825758 | METHODS OF TREATING OCULAR CONDITIONS | NEAGU, IRINA | — |
| 18049815 | LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1625 | 1 |
| 1638 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825758 | METHODS OF TREATING OCULAR CONDITIONS | NEAGU, IRINA | 1629 | §112DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18437748 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | ISMAIL, REHANA | 1625 | Other | Non-Final OA | 70d | Pending | Feb 09, 2024 |
| 18559512 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18049815 | LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | — | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOyster Point Pharma Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Irina Neagu has the most, with 1 of Oyster Point Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.